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Abstract
Background:  Age-related macular disease is the leading cause of blind registration in the
developed world. One aetiological hypothesis involves oxidation, and the intrinsic vulnerability of
the retina to damage via this process. This has prompted interest in the role of antioxidants,
particularly the carotenoids lutein and zeaxanthin, in the prevention and treatment of this eye
disease.
Methods: The aim of this randomised controlled trial is to determine the effect of a nutritional
supplement containing lutein, vitamins A, C and E, zinc, and copper on measures of visual function
in people with and without age-related macular disease. Outcome measures are distance and near
visual acuity, contrast sensitivity, colour vision, macular visual field, glare recovery, and fundus
photography. Randomisation is achieved via a random number generator, and masking achieved by
third party coding of the active and placebo containers. Data collection will take place at nine and
18 months, and statistical analysis will employ Student's t test.
Discussion: A paucity of treatment modalities for age-related macular disease has prompted
research into the development of prevention strategies. A positive effect on normals may be
indicative of a role of nutritional supplementation in preventing or delaying onset of the condition.
An observed benefit in the age-related macular disease group may indicate a potential role of
supplementation in prevention of progression, or even a degree reversal of the visual effects caused
by this condition.
Background
Epidemiology of age-related macular disease
Age-related macular degeneration is the leading cause of
registrable blindness in the developed world [1–3], and its
prevalence is expected to increase with the anticipated
demographic right-shift [4]. In order to standardise termi-
nology a classification system for age-related macular
degeneration has been developed [5]. Early and late stages
of the condition are termed age-related maculopathy
(ARM) and age-related macular degeneration (AMD)
respectively. The term age-related macular disease will be
used to encompass ARM and AMD.
Published: 10 October 2003
Nutrition Journal 2003, 2:12
Received: 03 July 2003
Accepted: 10 October 2003
This article is available from: http://www.nutritionj.com/content/2/1/12
© 2003 Bartlett and Eperjesi; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted 
in all media for any purpose, provided this notice is preserved along with the article's original URL.Nutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/12
Page 2 of 7
(page number not for citation purposes)
ARM is most often clinically apparent over the age of 50
years. The main symptom is increasing difficulty with fine
detail discrimination. AMD is categorised further in to
'non-neovascular AMD' (also known as dry AMD or geo-
graphic atrophy), and 'neovascular AMD' (also known as
wet, exudative, or disciform) [5]. Neovascular AMD refers
to the growth of new, weak blood vessels and their subse-
quent leakage in the macular region of the retina. Non-
neovascular AMD is the most common form, and is esti-
mated to be present in 15% of eyes by 80 years of age [6–
9]. Progression is slow and legal blindness has been esti-
mated to occur between 5 and 10 years [10]. Neovascular
AMD is less common, occurring in 5.2% of the popula-
tion over 75 years [2], but accounts for 90% of blind reg-
istrations [11]. Sufferers experience rapid, significant loss
of central vision. Neovascular AMD is generally preceded
by the non-neovascular form.
Clinicopathogenesis of age-related macular disease
The macula is around 5 mm in diameter and is located
centrally in the retina. It has a central depressed area, of
approximately 1.5 mm diameter, called the fovea. The
fovea is located approximately 4 mm temporal from the
optic disc. The central floor of the fovea is called the fove-
ola, which has a diameter of 0.35 mm and is the thinnest
part of the retina. It contains only cone photoreceptors
and their nuclei [12] (see figure 1).
Aetiology of AMD
The exact aetiology of AMD is not known, but several
hypotheses have been proposed:
Age-related change to Bruch's membrane and the retinal pigment 
epithelium (RPE)
The RPE lies between Bruch's membrane and the sensory
retina. It forms the blood-retina barrier and is involved
with vitamin A metabolism, transport of metabolites from
the choroid to the retina, manufacture of mucopolysac-
charides, and breakdown of damaged photoreceptor
outer segments. Bruch's membrane separates the RPE
from the choriocapillaris, which serves as the main blood
supply to the outer retina [12].
Increasing age promotes an increased lipid content of
Bruch's membrane, and the macula is affected by this
process to a greater extent than the periphery [13]. Conse-
quential changes to the diffusion characteristics of Bruch's
membrane may precipitate AMD [14].
Senescence of RPE cells occurs earlier than in other cell
types, such as fibroblasts [15]. Foveal RPE cells decrease in
density and selectively lose their hexagonal shape with age
[16,17]. These changes may contribute to the onset of
AMD.
Vascular insufficiency
Changes to the choroidal and scleral vasculature, and the
resulting increase in haemodynamic resistance have been
proposed to cause damage to the RPE [18,19]. Foveal cho-
riocapillaris blood flow is reduced with age, but has been
shown to be further degraded in AMD patients [20,21].
Laser Doppler flowmetry has been used to establish that
choroidal blood volume is reduced via decreased density
and diameter of the choriocapillaris [21].
Genetics
An increased risk of AMD has been demonstrated with a
positive family history [22,23], and this supports the pro-
posed genetic component to development of AMD. It is
likely that those with an inherited predisposition for the
condition will develop it following exposure to certain
risk factors [24].
Free radical/ oxidative stress hypothesis
Reactive oxygen intermediates is an inclusive term used to
describe both oxidants and free radical species [25]. A free
radical can be described as 'any atom or molecule that has
one or more unpaired electrons' [26]. Examples include
the superoxide anion (O2-•) and the hydroxyl free radical
(OH•). Oxidants such as singlet oxygen (102) and hydro-
gen peroxide (H202) contain paired electrons, but in a
reactive state [27]. It is proposed that many degenerative
diseases result from uncontrolled ROI reactions within
the body [28]. A free radical will attempt to achieve stabil-
ity by gaining electrons from other molecules. These mol-
ecules become 'reducing agents' by donating electrons
and are damaged by this process. In the retina this damage
may lead to the development of age-related macular dis-
ease. The retina is particularly susceptible to oxidative
stress for several reasons:
Human fundus Figure 1
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• The retina is subject to high levels of radiation, particu-
larly blue light.
• Oxygen consumption by the retina is greater than that of
other tissues [29].
• Photoreceptor outer segments contain a high propor-
tion of polyunsaturated fatty acids, whose double bonds
are a rich source of electrons [30,31].
• The retina contains photosensitisers, which make cells
and tissues sensitive to the influence of irradiation [32–
34]
• Phagocytosis by the RPE generates ROI [35].
The body has several defence mechanisms against free
radical damage, including antioxidant enzymes such as
superoxide dismutase and catalase, antioxidant vitamins
such as vitamins C, E and some carotenoids, and other
antioxidant compounds such as metallationein, melanin,
and glutathione. For a detailed account of the role of oxi-
dation in the pathogenesis of AMD, see Beatty et al.
(2000) [36].
Antioxidants and AMD
The lack of treatment options for AMD has prompted a
search for possible preventative strategies. The main risk
factors for AMD are increasing age [37–41], smoking [42–
44], and family history [22,45–47]. Proposed risk factors
include female gender [2,48], white ethnicity [49–51],
sunlight exposure [52,53], high dietary fat intake [54,55],
hypertension [38,56–58], and low antioxidant levels
[55,59]. It follows that the risk of developing ARM and
AMD may be reduced by lifestyle changes such as cessa-
tion of smoking, minimising sunlight exposure, reducing
dietary fat intake, and maintaining antioxidant levels. For
a review of randomised controlled trials investigating the
role of nutritional supplementation in age-related macu-
lar disease, see Bartlett and Eperjesi (2003) [60].
The role of lutein and zeaxanthin in prevention and 
treatment of age-related macular disease
The isometric carotenoids lutein, zeaxanthin, and meso-
zeaxanthin make up the macular pigment (MP) [61–63],
which appears clinically as a yellow colouration to the
macular area. Humans are unable to produce carotenoids
but use them in a variety of functions [64]. Carotenoids
are synthesised in plants, algae and bacteria [65], and the
normal Western diet contains 1.3–3 mg/day of lutein and
zeaxanthin combined [66,67].
Ocular tissues contain several carotenoids, but the retina
contains lutein and zeaxanthin exclusively [68]. Lutein
and zeaxanthin are present in rod outer segments, where
they would be most needed, and concentrations have
been shown to be higher in the macular region than the
peripheral retina [69]. This evidence supports the selective
uptake of lutein in the retina and suggests that it plays
important role in maintenance of ocular health.
A 70% reduced risk of AMD has been demonstrated with
high (>0.67 µmol/L) versus low (0.25 µmol/L) lutein/
zeaxanthin plasma levels [70]. A study of retinal levels of
lutein and zeaxanthin in donor eyes found an 82% lower
risk of AMD in retinae among the 25% with highest lutein
and zeaxanthin levels compared to the 25% with the low-
est levels [71]. Measurement of macular pigment optical
density (MPOD) in healthy eyes showed an age-related
decline, and healthy eyes considered to be at risk for AMD
had significantly less MP than healthy eyes not at risk
[72]. This evidence suggests that lower plasma and retinal
levels of lutein and zeaxanthin present an increased risk of
developing AMD.
Daily supplementation for 140 days with 30 mg of lutein
esters produced a seven fold increase in lutein serum lev-
els and a 20–40% increase in MPOD [73]. A 35% increase
in lutein serum levels and a 20% increase in MPOD was
demonstrated in a study supplementing 11 subjects daily
with 11 mg of lutein from 60 g of spinach and 150 g or
corn/maize [74]. Supplementation with 10 mg/day of
lutein esters for 12 weeks was shown to increase serum
lutein levels by five times and MPOD by approximately
20% [75]. These studies show that lutein supplementa-
tion does increase plasma and retinal lutein levels.
Lutein and zeaxanthin are believed to protect the retina in
two ways. Firstly, they act as blue-light filters. Action spec-
trum for blue-light induced damage shows a maximum at
400 nm and 450 nm, and this is consistent with the
absorption spectrum of macular pigment [76]. Secondly,
they are able to quench free radicals. Energy transfer to
them quenches singlet oxygen, and they are also believed
to react with peroxy radicals that are involved with lipid
peroxidation [77].
Objectives
To determine the effect of 18 months of daily lutein and
antioxidant supplementation on measures of visual func-
tion in subjects with and without age-related macular
disease.
Materials and Methods
Recruitment
The study requires recruitment of people with and with-
out age-related macular disease. Recruitment methods
employed include sending information to Birmingham
optometrists, ophthalmologists, and a specialist centre for
rehabilitation of people with sight loss, an editorial in theNutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/12
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Birmingham Evening Mail, recruitment e-mails sent to the
Royal National Institute for the Blind (RNIB) and all staff
and students at Aston University and Aston Science Park.
A project website has also been developed at http://
www.aston.ac.uk/lhs/research/nri/opo/amd. Data collec-
tion takes place in a standard consulting room at Aston
University. Enrolment, randomisation, and data collec-
tion are carried out by HB. HB and FE are masked to group
assignment. HB is a research optometrist and FE is an
optometrist and lecturer at Aston University, Birming-
ham, UK.
Inclusion/exclusion criteria
For inclusion participants a) have to provide written
informed consent, b) have to be available for three visits
to Aston University, c) have to present with no ocular
pathology in one eye, or no ocular pathology other than
dry AMD in one eye. A cataract grading system consisting
of grades one, two and three for each of cortical, nuclear,
and posterior subcapsular cataracts has been developed.
Participants presenting with lens opacities precluding fun-
dus photography are excluded. Throughout the trial
period, progression of any type of cataract to the succes-
sive grade will require the participant to withdraw.
Exclusion criteria include type I and II diabetes because
vitamin E has been shown to affect glucose tolerance [78–
82] and diabetic retinopathy may confound the results.
Those taking Warfarin medication are excluded as zinc
may decrease its absorption and activity [83], as are those
who use nutritional supplements that potentially raise
vitamin and mineral intake above safe limits. The most
recent guidelines for upper limits of nutritional supple-
mentation are set out in the UK Food Standards Agency
report [84]. Neovascular AMD and other ocular disease
that could potentially interfere with the results are
excluded.
Masking
The study formulation and placebo tablets have been pro-
duced by Quest Vitamins Ltd, Aston Science Park, Bir-
mingham, B7 4AP, and are identical in external and
internal appearance, and taste. The manufacturer has allo-
cated distinguishing symbols, µ and λ. The tablets are
packaged in identical, sealed, white containers; the only
difference being the symbol on the label. Investigators
and participants do not know which symbol represents
the placebo tablets, and which represents the active
formulation.
Intervention
The study formulation contains the following:
Lutein 6 mg
Vitamin A 750 µg
Vitamin C 250 mg
Vitamin E 34 mg
Zinc 10 mg
Copper 0.5 mg
Participants in both groups are instructed to take one tab-
let, at the same time every day, with food.
Randomisation
The random number generator function in Microsoft
Excel is being used to allocate participants to µ and λ
groups. Odd numbers allocate to the µ group.
Baseline data
On application, participants complete a health question-
naire, a food frequency questionnaire, and a food diary.
The health questionnaire provides information about
general health, medication, nutritional supplementation,
smoking history, ocular health, and time spent living
abroad. The food questionnaire and diary ask for informa-
tion about diet for analysis using Foodbase 2000 software
(The Institute of Brain Chemistry and Human Nutrition,
London N7 8DB).
Outcome measures
The investigation of several measures of visual function is
required, as age-related macular disease can produce vary-
ing signs and symptoms.
Visual acuity
Distance and near visual acuity (VA) measured using Bai-
ley-Lovie logMAR charts. LogMAR charts have 5 letters
and 0.1 log MAR progression per line. The advantage of
using these charts is that they provide an equal-interval
scale, and there are five letters per line. Standard Snellen
charts do not provide a linear scale and have a decreasing
number of letters per line as the letter size increases.
Contrast sensitivity
Contrast sensitivity (CS) is measured using a Pelli-Robson
chart (Clement Clarke International, Edinburgh Way,
Harlow, Essex, CM20 2TT, UK) and provides additional
information about vision. The Pelli-Robson chart deter-
mines the contrast required to read large letters and is
designed to test mid- to low-spatial frequencies. Some
people may have normal visual acuity, but reduced con-
trast sensitivity at low spatial frequencies, particularly if
they suffer from ocular pathologies such as age-related
macular disease.Nutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/12
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Colour vision
Colour vision measured using the PV-16 quantitative col-
our vision test (Precision Vision Inc, 944 First Street, La
Salle, IL, 61301, USA). Macular disease can cause a defi-
ciency in blue-yellow colour vision as the short-wave-
length photoreceptors are concentrated around the fovea.
Macular Mapping Test
Macular Mapping (MM) test (The Smith-Kettlewell
Research Institute, 2318 Fillmore Street, San Francisco,
CA, 94115, USA) was developed to map visual defects
caused by macular disease. It was developed by MacKeben
and Colenbrander [85] and differs from conventional
field analysis in that the stimuli are single letters rather
than spots of light. This is a novel piece of equipment and
each participant is given a practice run to eliminate learn-
ing effects. At the end of the test a single figure score is
presented.
Glare recovery
Eger Macular Stressometer (EMS) (Gulden Ophthalmics,
Elkins Park, PA 19027) is used to assess glare recovery,
also known as photostress recovery time (PSRT). This is
the time taken for the regeneration of photopigments in
bleached photoreceptors to a level that allows resolution
of, for example, a letter at near. Resynthesis of the photo-
pigments is dependent upon the integrity of the photore-
ceptors and RPE [86]; it follows that the PSRT may be
extended in those with diseases affecting these structures.
This is a novel piece of equipment and each participant is
given a practice run to eliminate learning effects.
Fundus photography
Fundus photographs of the macular will be assessed using
colour and edge analysis software.
Follow up
Data collection will take place at baseline, nine, and 18
months.
Analyses
For each outcome measure the change between baseline,
nine month, and 18 month values will be calculated. A
Student's t test will be used to determine whether the
means of these values differ at the 5% significance level
between the placebo and active formulation results for
age-related macular disease participants, and normal par-
ticipants, after differences in age, gender and diet have
been taken into account.
Power
From initial data collection we have calculated the treat-
ment group sizes required in order to have 80% power at
the 5% significance level for VA, CS, MM test, and the
EMS. These values suggest that a total of 63 normal, and
96 age-related macular disease participants are required.
Ethical approval
The study has been approved by the Aston University
Human Sciences Ethical Committee. The tenets of the
Declaration of Helsinki are being followed [87].
Discussion
Randomised masked trials differ from observational stud-
ies in that they have the ability to demonstrate causality.
The influence of confounding variables is reduced by ran-
dom assignment of participants to intervention groups,
and masking reduces the influence of investigator bias.
There is evidence for selective deposition of lutein in the
retina, increase of retinal and serum levels of lutein with
supplementation, and an increased risk of age-related
macular disease with reduced retinal lutein levels. This
randomised controlled trial will provide further informa-
tion regarding the effect of lutein and antioxidant supple-
mentation on specific measures of visual function in
people with and without age-related macular disease. The
current paucity of treatment modalities for this condition
has prompted research into the development of preven-
tion strategies. A positive effect of the supplementation on
normals may be indicative of its potential role in preven-
tion or delaying the onset of age-related macular disease.
This may be of particular importance for those with a pos-
itive family history, or exposure to other risk factors. A
positive effect in age-related macular disease affected eyes
may suggest a role of nutritional supplementation in pre-
vention of progression of the disease, or even in reversal
of symptoms.
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